Approval · Notice of Compliance 12516 · 2011
LUCENTIS: Notice of Compliance 12516
Issued July 25, 2011
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 12516
- Date
- July 25, 2011
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Priority
- Reason
- New Indication: Lucentis (ranibizumab) is indicated for the treatment of visual impairment due to macular edema secondary to retinal vein occlusion (RVO)
- Therapeutic class
- Anti-neovascularisation agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| LUCENTIS | Not yet assigned | — |
Medicinal ingredients
- RANIBIZUMAB 10 MG per ML